Therapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study
PLOS One · 19.03.2026 · 21 (3) · e0344948
DOI: 10.1371/journal.pone.0344948 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS One, online erschienen am 19.03.2026. Verfasst von Seo-Young Choi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Biomedical Research Institute, Republic…. Hauptthemen laut MEDLINE: Calcium Channel Blockers, Fructose, Nimodipine, Vestibular Migraine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Samjinpharm Co., Ltd.
Abstract (Originalsprache)
Background
Although new preventive treatments for migraine have emerged, it remains essential to validate the efficacy of established drugs to ensure broader therapeutic options for migraine and, in particular, for vestibular migraine where clinical evidence is more limited. This study aimed to assess the therapeutic effectiveness of nimodipine, an L-type calcium channel blocker, in patients with migraine and vestibular migraine, with reference to outcomes observed with topiramate.
Methods
Using a prospective open-label study involving nine referral-based university hospitals in South Korea, we recruited 850 patients (81% women, mean age ± SD = 41 ± 12) with migraine, including 255 with vestibular migraine. The primary outcome was the change in headache days over three months. The secondary outcomes included changes in pain rating scale, Migraine Disability Assessment Scale (MIDAS) and Headache Impact Test-6 (HIT-6). The outcomes of vestibular migraine included dizziness days and intensity, Dizziness Handicap Inventory, and UCLA-Dizziness Questionnaire.
Results
Of the 850 patients, 465 (55%) completed three months of evaluation (205 in the nimodipine group, 160 in the topiramate group, and 100 in the combination group). All groups showed a significant reduction in the headache days (1.2–2 days/week, p < 0.001) without inter-group differences ( p = 0.865). The topiramate group showed greater improvements in MIDAS and HIT-6 scores than the nimodipine ( p = 0.004) and combination groups ( p = 0.040). For vestibular migraine (n = 131), all groups improved in headache and dizziness outcomes ( p < 0.001) without inter-group differences. Adverse events leading to study discontinuation were observed only in 14 (2%) patients without a difference among the groups.
Conclusion
Nimodipine was associated with improvements in headache-related outcomes in migraine and in both headache- and dizziness-related outcomes in vestibular migraine. Given the observed improvements and favorable tolerability, nimodipine may be a valuable treatment option for migraine and vestibular migrain. Trial registration cris.nih.go.kr (KCT0010555).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Pusan National University Hospital, Pusan National University School of Medicine and Biomedical Research Institute, Republic of Korea.
- Department of Neurology, Jeonbuk National University Hospital & School of Medicine, Jeonju, Republic of Korea.
- Department of Neurology, Keimyung University School of Medicine, Daegu, Republic of Korea.
- Department of Neurology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea.
- Department of Neurology, Pusan National University School of Medicine, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea.
- Department of Neurology, College of Medicine, Seoul National University, Seoul, Republic of Korea.
ORCID-Profile: Ji-Soo Kim
Förderung
- Samjinpharm Co., Ltd
Zitieren
APA
Choi, S. Y., Oh, S. Y., Kim, H. A., Park, J. Y., Choi, J. H., Oh, E. H., Choi, J. Y., Jeong, S. H., Lee, S. H., Kim, J. M., Kim, S. H., Kim, H. J., Choi, K. D., & Kim, J. S. (2026). Therapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study. PLOS One, 21(3), e0344948. https://doi.org/10.1371/journal.pone.0344948
Vancouver
Choi SY, Oh SY, Kim HA, Park JY, Choi JH, Oh EH, et al. Therapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study. PLOS One. 2026;21(3):e0344948. doi:10.1371/journal.pone.0344948
BibTeX
@article{Choi2026,
author = {Choi, Seo-Young and Oh, Sun-Young and Kim, Hyun Ah and Park, Ji-Yun and Choi, Jae-Hwan and Oh, Eun Hye and Choi, Jeong-Yoon and Jeong, Seong-Hae and Lee, Seung-Han and Kim, Jae-Myung and Kim, Sang-Ho and Kim, Hyo-Jung and Choi, Kwang-Dong and Kim, Ji-Soo},
title = {Therapeutic efficacy of nimodipine and topiramate on migraine and vestibular migraine; A prospective multicenter open-label study},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {3},
pages = {e0344948},
doi = {10.1371/journal.pone.0344948}
}
EUVIMED